Critical Therapeutics, Inc.

Company licenses exclusive rights to cinnamylidene-anabaseines compounds

Published in Medical Device Law Weekly, October 10th, 2004

Critical Therapeutics, Inc., (CRTX), a biopharmaceutical company focused on the discovery, development, and commercialization of products for respiratory, inflammatory, and critical care diseases, announced that it has licensed rights to a key patent from the University of Florida.

The company's license to U.S. patent no. 5,977,144 provides exclusive composition-of-matter and method-of-use rights to a family of compounds known as cinnamylidene-anabaseines. These compounds target and stimulate the nicotinic alpha-7 cholinergic receptor. Preclinical studies have demonstrated that the alpha-7 receptor on the macrophage cell plays an important role in regulating the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Law Weekly

Source: Medical Device Law Weekly (2004-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry